Samuraciclib

• Target :

  Others|||Apoptosis|||CDK

• Related Pathways :

  Cell Cycle/Checkpoint|||Others|||Apoptosis

• Bioactivity :

  Samuraciclib (CT7001) is a potent, selective, and orally active CDK7 inhibitor with an ATP-competitive nature, effectively inhibiting CDK7 with an IC50 of 41 nM. It demonstrates 45-fold, 15-fold (IC50 of 578 nM), 230-fold, and 30-fold selectivity over CDK1, CDK2, CDK5, and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values of 0.2-0.3 ?M and possesses anti-tumor effects [1] [2].

• Smiles :

  N(CC1=CC=CC=C1)C=2N3C(=C(C(C)C)C=N3)N=C(NC[C@@H]4[C@@H](O)CNCC4)C2

• Molecular Formula :

  C22H30N6O

• Molecular Weight :

  394.51

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  1805833-75-3